NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP)

Historical Holders from Q1 2020 to Q4 2025

Type / Class
Equity / Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares)
Symbol
NBP on Nasdaq
Shares outstanding
264,351,875
Price per share
$3.97
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
29,690,135
Total reported value
$112,309,052
% of total 13F portfolios
0%
Share change
+20,297,042
Value change
+$77,501,729
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
42
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Everest Medicines Ltd 16% $36,146,009 42,524,716 Everest Medicines Limited 05 Aug 2025
CBC Investment I-Mab Ltd 10% -42% $23,368,706 -$5,166,783 27,492,595 -18% Wei Fu 05 Aug 2025
As of 30 Sep 2025, NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP) has 42 institutional shareholders filing 13F forms. They hold 29,690,135 shares of 264,351,875 outstanding shares (11%) .

Top 25 institutional shareholders own 11% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
JANUS HENDERSON GROUP PLC 3% 7,991,377 0.01% $30,287,319
HHLR ADVISORS, LTD. 2.3% 5,980,568 0% 0.55% $22,606,547
ADAGE CAPITAL PARTNERS GP, L.L.C. 1.3% 3,338,034 0.02% $12,617,769
MORGAN STANLEY 0.84% 2,232,040 +3729% 0% $8,437,112
Ariose Capital Management Ltd 0.64% 1,704,393 +1667% 2.2% $6,442,606
Exome Asset Management LLC 0.54% 1,439,604 3.7% $5,441,703
Siren, L.L.C. 0.44% 1,165,957 0.17% $4,407,317
Candriam S.C.A. 0.43% 1,132,563 0% 0.02% $4,281,088
Woodline Partners LP 0.4% 1,050,000 0.02% $3,969,000
Point72 Hong Kong Ltd 0.21% 561,366 0.1% $2,121,963
SG Americas Securities, LLC 0.18% 463,894 -47% 0.01% $1,754,000
BARCLAYS PLC 0.15% 395,431 +1202% 0% $1,494,729
STATE STREET CORP 0.13% 337,400 0% $1,275,372
UBS Group AG 0.11% 295,078 +60% 0% $1,115,395
GOLDMAN SACHS GROUP INC 0.08% 218,470 +1945% 0% $825,817
Connor, Clark & Lunn Investment Management Ltd. 0.06% 164,064 +490% 0% $620,162
JPMORGAN CHASE & CO 0.06% 150,164 0% $567,620
SUPERSTRING CAPITAL MANAGEMENT LP 0.05% 139,886 0.52% $528,769
BNP PARIBAS FINANCIAL MARKETS 0.05% 119,512 0% 0% $451,755
ALPS ADVISORS INC 0.04% 111,490 0% $421,432
LMR Partners LLP 0.04% 100,000 0% $378,000
DIMENSIONAL FUND ADVISORS LP 0.04% 98,776 +69% 0% $373,373
Point72 Asset Management, L.P. 0.03% 77,348 0% $292,376
XTX Topco Ltd 0.03% 72,104 0.01% $272,553
RENAISSANCE TECHNOLOGIES LLC 0.02% 63,600 -0.16% 0% $240,408

Institutional Holders of NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 36,481 $145,000 -$1,698,838 397.47% 1
2025 Q3 29,690,135 $112,309,052 +$77,501,729 378% 42
2025 Q2 9,395,986 $22,737,366 +$2,030,864 242% 32
2025 Q1 8,993,007 $7,408,233 -$2,236,624 82.39% 29
2024 Q4 11,912,678 $10,125,354 -$4,196,491 85% 27
2024 Q3 14,193,703 $17,600,522 -$1,644,775 124% 27
2024 Q2 15,140,525 $25,329,475 +$4,917,137 167% 37
2024 Q1 12,194,479 $22,682,620 +$350,985 186% 39
2023 Q4 12,343,395 $23,450,292 -$3,034,254 190% 43
2023 Q3 15,250,209 $20,127,696 -$8,379,698 132% 46
2023 Q2 18,691,045 $55,880,438 -$6,382,939 299% 46
2023 Q1 20,700,388 $71,623,449 -$16,503,641 346% 52
2022 Q4 24,857,032 $103,893,915 -$23,565,532 418% 63
2022 Q3 30,742,440 $123,259,030 -$78,443,042 401% 67
2022 Q2 34,856,372 $392,510,033 -$52,532,853 1,130% 88
2022 Q1 38,649,685 $627,879,820 -$5,114,541 1,624% 110
2021 Q4 38,862,958 $1,843,568,179 +$59,854,597 4,739% 126
2021 Q3 36,035,033 $2,613,664,662 +$445,147,637 7,248.97% 140
2021 Q2 28,287,913 $2,375,235,906 +$494,893,838 8,395.01% 135
2021 Q1 23,173,297 $1,123,137,433 +$496,891,577 4,846.98% 79
2020 Q4 12,179,959 $574,089,000 +$198,056,631 4,714.98% 60
2020 Q3 42,167 $1,636,000 +$40,120 4,005.46% 4
2020 Q2 3,298,968 $97,724,000 -$3,594,280 2,993.22% 19
2020 Q1 3,439,668 $44,717,000 +$44,716,979 1,300% 15